Tumor necrosis factor-α processing inhibitor-1 inhibits skin fibrosis in a bleomycin-induced murine model of scleroderma

Experimental Dermatology

Volumn 19, Issue 1, 2010, Pages 38-43

  Terao, Mika ^a   Murota, Hiroyuki ^a   Kitaba, Shun ^a   Katayama, Ichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Scleroderma; TAPI 1; Tumor necrosis factor receptor p55; Tumor necrosis factor ; Tumor necrosis factor converting enzyme

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; COLLAGEN TYPE 1; MESSENGER RNA; PROTEIN P55; PROTEIN P75; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; IC 50; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KERATINOCYTE; LOW DRUG DOSE; MOUSE; MUSCLE CELL; MYOFIBROBLAST; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SCLERODERMA; SKIN FIBROSIS; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS;

ADAM PROTEINS; ANIMALS; ANIMALS, NEWBORN; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CELL LINE; COLLAGEN TYPE I; DIPEPTIDES; FEMALE; FIBROBLASTS; HUMANS; HYDROXAMIC ACIDS; KERATINOCYTES; MICE; MICE, INBRED C57BL; MUSCLE FIBERS, SKELETAL; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 72549108357     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00973.x     Document Type: Article

References (27)

1. Denton C P, Black C M, Abraham D J. Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol 2006, 2:134-144.
2. Steen V. Targeted therapy for systemic sclerosis. Autoimmun Rev 2006, 5:122-124.
3. Trojanowska M, LeRoy E C, Eckes B, Krieg T. Pathogenesis of fibrosis: type 1 collagen and the skin. J Mol Med 1998, 76:266-274.
4. Uitto J, Kouba D. Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 2000, 24(Suppl. 1):S60-S69.
5. Leask A, Denton C P, Abraham D J. Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol 2004, 122:1-6.
6. McGaha T L, Bona C A. Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun Rev 2002, 1:174-181.
7. Abraham D J, Shiwen X, Black C M, Sa S, Xu Y, Leask A. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000, 275:15220-15225.
8. Yamane K, Ihn H, Asano Y, Jinnin M, Tamaki K. Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts. J Immunol 2003, 171:3855-3862.
9. Kahari V M, Chen Y Q, Su M W, Ramirez F, Uitto J. Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1. Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels. J Clin Invest 1990, 86:1489-1495.
10. Murota H, Hamasaki Y, Nakashima T, Yamamoto K, Katayama I, Matsuyama T. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts. Arthritis Rheum 2003, 48:1117-1125.
11. Hebbar M, Gillot J M, Hachulla E. Early expression of E-selectin, tumor necrosis factor alpha, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum 1996, 39:1161-1165.
12. Alecu M, Geleriu L, Coman G, Galatescu L. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med 1998, 36:251-259.
13. Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993, 13:321-328.
14. Gruschwitz M S, Albrecht M, Vieth G, Haustein U F. In situ expression and serum levels of tumor necrosis factor-alpha receptors in patients with early stages of systemic sclerosis. J Rheumatol 1997, 24:1936-1943.
15. Majewski S, Wojas-Pelc A, Malejczyk M, Szymanska E, Jablonska S. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 1999, 79:207-210.
16. Black R A, Rauch C T, Kozlosky C J. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997, 385:729-733.
17. Newton R C, Solomon K A, Covington M B. Biology of TACE inhibition. Ann Rheum Dis 2001, 60(Suppl. 3):iii25-iii32.
18. Sano S, Itami S, Takeda K. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J 1999, 18:4657-4668.
19. Gallucci R M, Sloan D K, Heck J M, Murray A R, O'Dell S J. Interleukin 6 indirectly induces keratinocyte migration. J Invest Dermatol 2004, 122:764-772.
20. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005, 115:1-20.
21. Kissin E Y, Merkel P A, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006, 54:3655-3660.
22. Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 2009, 3 March
23. Bohgaki T, Amasaki Y, Nishimura N. Up regulated expression of tumour necrosis factor{alpha}converting enzyme in peripheral monocytes of patients with early systemic sclerosis. Ann Rheum Dis 2005, 64:1165-1173.
24. Tutuncu Z, Morgan G J, Kavanaugh A. Anti-TNF therapy for other inflammatory conditions. Clin Exp Rheumatol 2002, 20:S146-151.
25. Alexis A F, Strober B E. Off-label dermatologic uses of anti-TNF-a therapies. J Cutan Med Surg 2005, 9:296-302.
26. Koca S S, Isik A, Ozercan I H, Ustundag B, Evren B, Metin K. Effectiveness of etanercept in bleomycin-induced experimental scleroderma. Rheumatology (Oxford) 2008, 47:172-175.
27. Chizzolini C, Parel Y, De Luca C. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003, 48:2593-2604.